The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
